SCHEMBL5408426

SCHEMBL5408426

CCOC(=O)c1coc([C@H](CCCC2CCCCC2)CC(=O)OC(C)(C)C)n1

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 20/20 0.55
MMP2 P08253 2/20 0.52
MMP3 P08254 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5404198 0.89 BMP1 (0.58) BMP1MMP2
SCHEMBL27586684 0.89 BMP1 (0.58) BMP1MMP2
SCHEMBL6428661 0.86 BMP1 (0.52) BMP1MMP2MMP3
SCHEMBL6428256 0.86 BMP1 (0.74) BMP1MMP2MMP3
Trifluoroacetic Acid SCHEMBL27567214 0.84 BMP1 (0.54) BMP1MMP2
Trifluoroacetic Acid SCHEMBL6428660 0.84 BMP1 (0.54) BMP1MMP2
SCHEMBL5406890 0.83 BMP1 (0.75) BMP1MMP2MMP3
SCHEMBL27567212 0.83 BMP1 (0.69) BMP1MMP2MMP3
SCHEMBL27567215 0.83 BMP1 (0.69) BMP1MMP2MMP3
SCHEMBL6599362 0.80 BMP1 (0.63) BMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7214694-B2 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors PFIZER INC (US) 2007-05-08 US disclosed
US-7214694-B2 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors PFIZER INC (US) 2007-05-08 US disclosed
EP-1343771-B1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2006-04-12 EP disclosed
EP-1373231-B1 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS PFIZER LTD (GB) 2005-06-08 EP disclosed
US-6897306-B2 3-heterocyclylpropanohydroxamic acids PFIZER PRODUCTS, INC. (US) 2005-05-24 US disclosed
US-6831088-B2 Wound healing agents; antiscarring agents PFIZER INC. 2004-12-14 US disclosed
EP-1240152-B1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2004-12-08 EP disclosed
US-20040142986-A1 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors DATTA USA (GB) 2004-07-22 US disclosed
US-6716861-B2 HETEROCYCLIC 1,2,4-OXADIAZOLE OR OXAZOLE RING CONTAINING PROPANOHYDROXAMIC ACIDS USEFUL AS ANTISCARRING AGENT PFIZER, INC. 2004-04-06 US disclosed
US-20040058917-A1 3-Heterocyclylpropanohydroxamic acid PCP inhibitors FISH PAUL VINCENT (GB) 2004-03-25 US disclosed
EP-1343771-A1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2003-09-17 EP disclosed
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids BAILEY SIMON (US) 2003-06-26 US disclosed
US-20020187979-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors FISH PAUL VINCENT (GB) 2002-12-12 US disclosed
US-20020151535-A1 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors PFIZER, INC 2002-10-17 US disclosed
WO-2002079175-A1 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID PCP INHIBITORS PFIZER LIMITED (GB) 2002-10-10 WO disclosed
EP-1240152-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2002-09-18 EP disclosed
US-6448278-B2 ANTISCARRING AGENT PFIZER INC. 2002-09-10 US disclosed
WO-2002050046-A1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2002-06-27 WO disclosed
US-20010021718-A1 Procollagen C-proteinase inhibitors PFIZER INC. 2001-09-13 US disclosed
WO-2001047901-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021718-A1 Procollagen C-proteinase inhibitors MMP1, CTSL, PREP BMP1 166/4885MMP2 16/4885MMP3 8/4885
US-20040058917-A1 3-Heterocyclylpropanohydroxamic acid PCP inhibitors PAH, FAP, PREP BMP1 77/4885MMP2 34/4885MMP3 38/4885
US-20020187979-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors MMP1, CPA1, PAH BMP1 26/4885MMP2 28/4885MMP3 32/4885
US-20020151535-A1 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors ALPI, TIMP3, MMP1 BMP1 376/4885MMP2 22/4885MMP3 9/4885
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids CPA1, MMP1, PREP BMP1 79/4885MMP2 11/4885MMP3 18/4885
US-20040142986-A1 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors ALPI, TIMP3, MMP1 BMP1 376/4885MMP2 22/4885MMP3 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.